Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

This study has been completed.
Spectrum Pharmaceuticals, Inc
Information provided by (Responsible Party):
TopoTarget A/S Identifier:
First received: December 18, 2006
Last updated: November 29, 2013
Last verified: November 2013

This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing schedule.

Condition Intervention Phase
Solid Tumor
Drug: oral belinostat
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by TopoTarget A/S:

Primary Outcome Measures:
  • Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort [ Time Frame: throughout the study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
  • Explore anti-tumor activity [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
  • Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphoma [ Time Frame: throughout the trial ] [ Designated as safety issue: Yes ]

Enrollment: 121
Study Start Date: June 2006
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: oral belinostat Drug: oral belinostat
oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
Other Name: PXD101


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years
  • Solid tumor: Histologically confirmed solid tumors.
  • Lymphoma: relapsed or refractory B-cell or T-cell lymphoma, NK-cell lymphoma or Hodgkin's disease (NK-cell = natural killer cell)
  • At least one evaluable lesion. Lesions must be evaluated by computed tomography (CT), magnetic resonance imaging (MRI), or bone scan. Patients with prostate cancer, bone disease and rising prostate-specific antigen (PSA) but no other evaluable disease are eligible and will be evaluated based on PSA. For lymphoma patients, lesions can also be measured by PET and/or evaluated in peripheral blood or bone marrow.
  • Progressive disease: Progressive disease will be defined as new or progressive lesions on CT-scan, MRI, bone scan or by rising PSA
  • ≥ 4 weeks since prior radiation therapy or chemotherapy
  • Karnofsky performance ≥ 60%
  • Solid Tumor: Acceptable liver, renal and bone marrow function to include:

    • absolute neutrophil count ≥ 1.5 x 10^9/L
    • hemoglobin ≥ 9.0 g/dl
    • platelets ≥ 100 x 10^9/L
    • bilirubin ≤ 1.5 x upper limit of normal (ULN)
    • AST and ALT ≤ 3.0 x ULN (≤ 5.0 x ULN is acceptable if liver has tumor involvement) (AST=aspartate aminotransferase, ALT=alanine aminotransferase)
    • serum creatinine ≤ 1.5 x ULN
    • PT-INR/PTT ≤ 1.5 x ULN, or for patients on anticoagulation therapy, status within therapeutic range (PT-INR/PTT = prothrombin-international normalized ratio/prothrombin time)
  • Lymphoma: Acceptable liver, renal and bone marrow function including the following:

    • absolute neutrophil count ≥ 1.0 x 10^9/L
    • platelets ≥ 50 x 10^9/L
    • bilirubin ≤ 1.5 x upper limit of normal (ULN), or ≤3 times ULN if documented hepatic involvement with lymphoma, or ≤5 times ULN if history of Gilbert's disease
    • AST and ALT ≤ 3.0 x ULN (≤ 5.0 x ULN is acceptable if liver has tumor involvement)
    • serum creatinine ≤ 1.5 x ULN
    • PT-INR/PTT ≤ 1.5 x ULN, or in the therapeutic range if on anticoagulation therapy
  • Serum potassium within normal range
  • Estimated life expectancy of greater than 3 months
  • Signed informed consent prior to any study specific procedures

Exclusion Criteria:

  • Prior treatment with PXD101
  • Within 4 weeks of enrollment:

    • major surgery
    • metastatic disease requiring palliative treatment
    • Anticancer therapy, including:

      • chemotherapy
      • radiotherapy
      • endocrine therapy
      • immunotherapy
      • other investigational agents (6 weeks for mitomycin or nitrosourea)
      • Lymphoma patients: No anticancer therapy within 2 weeks except for Rituximab which patients should be off for greater than 3 months unless there is evidence of disease progression.
  • Serious concomitant systemic disorders (eg, active infection) compromising patient safety.
  • Symptomatic brain metastases
  • Significant cardiovascular disease, including:

    • unstable angina pectoris
    • uncontrolled hypertension
    • congestive heart failure (New York Heart Association (NYHA) Class III or IV) related to primary cardiac disease, a condition requiring anti-arrhythmic therapy
    • ischemic or severe valvular heart disease
    • myocardial infarction within 6 months prior to the trial entry
  • A marked baseline prolongation of QT/QTc interval, such as:

    • repeated demonstration of a QTc interval > 500 msec (QTc=corrected QT interval)
    • Long QT syndrome
    • required use of concomitant medication on dosing days that may cause torsade de pointes
  • Altered mental status precluding understanding of the informed consent process and/or completion of the study
  • Pregnant or breast-feeding women
  • Refusal or inability to use effective means of contraception (for men and women of childbearing potential)
  • History of, or test positive for, HIV.
  • Lymphoma patients who have relapsed within 100 days of autologous or allogenic transplantation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00413075

United States, Connecticut
Yale New Haven Hospital
New Haven, Connecticut, United States, 06520
United States, New York
Columbia University - Herbert Irving Cancer Center
New York, New York, United States, 01132
New York University Cancer Institute
New York, New York, United States, 10016
United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77230-1402
Research Facility
Copenhagen, Denmark
United Kingdom
Research Facility
London, Surrey, United Kingdom, SW3 6JJ
Sponsors and Collaborators
TopoTarget A/S
Spectrum Pharmaceuticals, Inc
Principal Investigator: William Kevin Kelly, MD Yale University
  More Information

No publications provided

Responsible Party: TopoTarget A/S Identifier: NCT00413075     History of Changes
Obsolete Identifiers: NCT00411476
Other Study ID Numbers: PXD101-CLN-9
Study First Received: December 18, 2006
Last Updated: November 29, 2013
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Denmark: Danish Medicines Agency

Keywords provided by TopoTarget A/S:
Solid tumors
B-cell lymphoma
bladder cancer
Breast cancer
Carcinoma, Non-Small-Cell Lung
Carcinoma, Small Cell
colorectal cancer
Esophageal Neoplasms
head and neck cancer
Hodgkins Disease
kidney cancer
lung cancer
mesothelioma, cystic
Mixed Tumor, Mesodermal
Otorhinolaryngologic Neoplasms
Ovarian cancer
Parathyroid Neoplasms
Prostate cancer
T-cell lymphoma

Additional relevant MeSH terms:
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Antineoplastic Agents
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on October 21, 2014